Suppr超能文献

[受体反应性方法(RRM):一种估计药理激动剂在其受体处浓度的新方法]

[The receptorial responsiveness method (RRM): a new possibility to estimate the concentration of pharmacologic agonists at their receptors].

作者信息

Pák Krisztián, Kiss Zsuzsanna, Erdei Tamás, Képes Zita, Gesztelyi Rudolf

出版信息

Acta Pharm Hung. 2014;84(1):38-52.

Abstract

Cardiovascular disease is the biggest challenge in terms of life expectancy in developed countries. Adenosine contributes to the adaptation of the heart to ischemia and hypoxia, because adenosine, in addition to its metabolite role in the nucleic acid metabolism, is the endogenous agonist of the ubiquitous adenosine receptor family. Adenosine receptor activation is beneficial in most cases, it improves the balance between energy supply and consumption, reduces injury caused by stressors and inhibits the unfavorable tissue remodeling. Pharmacological manipulation of cardioprotective effects evoked by adenosine is an important, although to date not sufficiently utilized endeavor that may have therapeutic and preventive implications in cardiovascular diseases. As the ligand binding site of adenosine receptors is accessible from the extracellular space, it is especially important to know the adenosine concentration of the interstitial fluid (Ado). However, in the functioning heart, Ado values range in an extremely wide interval, spanning from nano- to micromolar concentrations, as estimated by the commonly used methods. Our recently developed procedure, the receptorial responsiveness method (RRM), may resolve this problem in certain cases. RRM enables quantification of an acute increase in the concentration of a pharmacological agonist, uniquely in the microenvironment of the receptors of the given agonist. As a limitation, concentration of agonists with short half-life (just like adenosine) at their receptors can only be quantified with the equieffective concentration of a stable agonist exerting the same action. In a previous study using RRM, inhibition of the transmembrane nucleoside transport in the euthyroid guinea pig atrium produced an increase in Ado that was equieffective with 18.8 +/- 3 nM CPA (N6-cyclopentyladenosine, a stable, selective A1 adenosine receptor agonist). This finding is consistent with observations of others, i.e., in the normoxic heart, adenosine flow is directed into the cell interior, and thus transport blockade elevates the extracellular adenosine level. In turn, nucleoside transport inhibition in the hyperthyroid guinea pig atrium caused a rise in Ado equieffective with 46.5 +/- 13.7 nM CPA. In sum, our work team was the first to demonstrate that adenosine transport in the hyperthyroid atrium has the same direction but is more intense as/than that in the euthyroid one.

摘要

在发达国家,心血管疾病是预期寿命方面面临的最大挑战。腺苷有助于心脏适应缺血和缺氧,因为腺苷除了在核酸代谢中发挥代谢物作用外,还是普遍存在的腺苷受体家族的内源性激动剂。在大多数情况下,腺苷受体激活是有益的,它能改善能量供应与消耗之间的平衡,减少应激源造成的损伤,并抑制不良的组织重塑。对腺苷引发的心脏保护作用进行药理学调控是一项重要的工作,尽管迄今为止尚未得到充分利用,但这可能对心血管疾病具有治疗和预防意义。由于腺苷受体的配体结合位点可从细胞外空间进入,了解组织间液中的腺苷浓度(Ado)尤为重要。然而,在正常运作的心脏中,根据常用方法估计,Ado值的范围极广,从纳摩尔到微摩尔浓度。我们最近开发的方法,即受体反应性方法(RRM),在某些情况下可能解决这个问题。RRM能够在给定激动剂受体的微环境中,独特地定量药理学激动剂浓度的急性增加。作为一个限制,半衰期短的激动剂(如腺苷)在其受体处的浓度只能用发挥相同作用的稳定激动剂的等效浓度来定量。在之前一项使用RRM的研究中,对正常甲状腺豚鼠心房跨膜核苷转运的抑制导致Ado增加,其等效于18.8±3 nM CPA(N6-环戊基腺苷,一种稳定的、选择性A1腺苷受体激动剂)。这一发现与其他人的观察结果一致,即在常氧心脏中,腺苷流向细胞内部,因此转运阻断会提高细胞外腺苷水平。反过来,对甲状腺功能亢进豚鼠心房的核苷转运抑制导致Ado升高,其等效于46.5±13.7 nM CPA。总之,我们的工作团队首次证明,甲状腺功能亢进心房中的腺苷转运方向与正常甲状腺心房相同,但更为强烈。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验